OncoMatch/Clinical Trials/NCT05213884
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Is NCT05213884 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Camrelizumab and Concurrent cisplatin chemotherapy for head and neck squamous cell carcinoma.
Treatment: Camrelizumab · Concurrent cisplatin chemotherapy — This is a phase 2, single-arm clinical trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 Blockade camrelizumab combined with induction chemotherapy followed by concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally advanced head and neck squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA, IVB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent.
Lab requirements
Blood counts
Adequate bone marrow function.
Kidney function
Adequate renal function.
Liver function
Adequate liver function.
Adequate bone marrow function. Adequate renal and liver function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify